An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 18 Aug 2025
At a glance
- Drugs MRG 007 (Primary)
- Indications Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Miracogen
Most Recent Events
- 01 Aug 2025 Status changed from not yet recruiting to recruiting.
- 15 Jul 2025 Status changed from planning to not yet recruiting.
- 03 Feb 2025 New trial record